Article: Cephalon Launches PROVIGIL(R) (modafinil) in the Republic of Ireland.

WEST CHESTER, Pa., Feb. 2 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today the availability of PROVIGIL(R) (modafinil) tablets in the Republic of Ireland for the treatment of narcolepsy. PROVIGIL is the first pharmaceutical product licensed by the Irish Medicines Board for treatment of this disorder. The company's European subsidiary, Cephalon U.K. Ltd., which currently markets the drug in the United Kingdom, also will market PROVIGIL to sleep specialists and neurologists in Ireland.

Narcolepsy is a chronic, neurological, lifelong sleep disorder that generally begins in young adulthood. Often, 10 to 15 years may pass between onset of symptoms and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!